Page 2 - Michael Strapazon News Today

Very low LDL-C Levels Data Reinforces Long-Term Efficacy and Consistent Safety Profile of Repatha Observed in FOURIER-OLE THOUSAND OAKS, Calif., N...

/PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the American Heart Association (AHA) Scientific...

/PRNewswire/ -- (Oct. 6, 2022) – Amgen (NASDAQ:AMGN) today announced the opening of a new research and development site in San Franciscos Oyster Point,...

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from two significant Phase 3 clinical studies of oral Otezla® (apremilast), demonstrating efficacy...

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today presented new compelling data from the Phase 3 FOURIER open label extension (OLE) studies of Repatha® (evolocumab) in...

Earlier Treatment With Repatha Resulted in a Lower Incidence of Major CV Events, Including CV Death80% of Patients Achieved Guideline Directed LDL-C L

Founding and Lead Sponsor in Collaboration with the Vice Provost of Advances in Learning at Harvard UniversityTHOUSAND OAKS, Calif., June 20, 2022...

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive topline data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran (formerly AMG...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced top-line results from two Repatha® (evolocumab) open label extension (OLE) studies to the Phase 3 FOURIER...